demonstrate

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

-- Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company and A...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company (NYSE: BMY...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Nationwide MRSA Prevalence Study to Demonstrate Full Scope of 'Superbug' Threat Facing U.S. Healthcare Facilities and Patients

Broadest, Most Comprehensive Survey Provides New Benchmark on MRSAin Healthcare Facilities WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- Thefollowing was released today by APIC: WHAT: -- First nationwide study of the prevalence of Methicillin-resistant Staphylococcus aureus (MRSA), a virulent multi-drug resistant organism, in U.S. healthcare facilit...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced results regarding theefficacy and safety of ORENCIA(R) (abatacept) from the open-labelphase of an ongoing investigational study in children with juvenileidiopathic arthritis (JIA) who have had an inadequate response toone or more disease-modifying anti- rheumatic drugs (DMARDs), suchas m...

Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia

MINNEAPOLIS, June 13, 2007 /PRNewswire/ -- Two studies presentedtoday demonstrated that Rozerem did not affect body sway at peakplasma levels, nor did it impair middle-of-the-night balance,mobility or memory performance in patients who suffer from chronicinsomnia. The results of the studies were presented at the 21stAnnual Meeting of the Associated Professional Sleep Societies(APSS)....

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicatedto the commercialization of products for a variety of malignant,degenerative and auto-immune indications, announced today thatPluristem's PLacenta eXpanded (PLX) cells have been demonstrated invitro to have properties that the Company believes gives thesecells th...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - GeronCorporation's (Nasdaq:GERN) telomerase inhibitor cancer drug,GRN163L, has demonstrated good pharmacokinetics and tolerability inits ongoing Phase I/II trial involving patients with chroniclymphocytic leukemia (CLL), according to data presented today byAlan Colowick, M.D., M.P.H., the company's president, oncology, atthe Pan Pacific Ly...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today released top-line findingsfrom its six month study of Proellex in the treatment ofendometriosis. This study, conducted in Europe, enrolled 39premenopausal women and has completed six months of dosing. Thestudy included three dose levels of Proellex(TM) as well as apositive control arm. The po...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex -the novel selective relaxant binding agent (SRBA) being developedby Organon, the human healthcare business unit of Akzo Nobel -demonstrated in a Phase III pivotal trial a 9-12 times fasterreversal of neuromuscular blockade as compared to neostigmine,without evidence of post operative residual curarization (PORC) orre-occurre...

Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification

SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX NewsNetwork) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com )announced today that it presented a mathematical comparison of a"Staggered Start" and a "Randomized Withdrawal" clinical trialdesign with a "Natural History Staggered Start" clinical trialdesign at the Alzheime...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

OSS, the Netherlands, June 11, 2007-Sugammadex - the novelselective relaxant binding agent (SRBA) being developed by Organon,the human healthcare business unit of Akzo Nobel - demonstrated ina Phase III pivotal trial a 9-12 times faster reversal ofneuromuscular blockade as compared to neostigmine, without evidenceof post operative residual curarization (PORC) or re-occurrence ofmuscle relax...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network)-- Endo Pharmaceuticals Inc., a wholly owned subsidiary of EndoPharmaceuticals Holdings Inc. (NASDAQ: ENDP), has presented resultsfrom a Phase III randomized, double-blind, placebo-controlledclinical trial evaluating Frova (frovatriptan succinate) 2.5 mgtablets as a six-day preventative treatment in women withdifficult-to-tre...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks

Nearly Twice as Many Patients Taking Trexima were Migraine FreeCompared to Placebo CHICAGO, June 08, 2007 /PRNewswire/ -- New data from two largetrials show that Trexima, when taken early, was nearly twice aseffective as placebo in eliminating all traditional migrainesymptoms at two and four hours across multiple attacks with justone tablet. The findings will be presented tomorrow at the...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

NYON, Switzerland, June 07, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today analysis of resultsdemonstrating that the Company's HIV vaccine elicited neutralizingIgA mucosal antibodies in a non-human primate model. Mucosal IgAantibodies are considered as a possible first line of defenseagainst infection by HIV. The data were presented by SylvainFleury, Ph.D., Mymetics'...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma ReportedToday at ASCO Annual Meeting PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plcannounced today long-term efficacy data from a Phase II trial of asingle one-week course of frontline treatment with the BEXXAR(R)Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in76 patients with newly diagnosed advanced...

Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study

COPENHAGEN, June 4, 2007-A new study published today in thejournal Current Medical Research and Opinion showed thatCipralex® (escitalopram) was superior to Cymbalta®(duloxetine) in the acute treatment of patients with majordepressive disorder (MDD) and was at least as efficacious inlong-term treatment. The study directly compared Cipralex® (anallosteric serotonin reuptake inh...

Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer

CHICAGO/DARMSTADT, Germany, June 4, 2007 – Data presentedtoday at this year’s American Society of Clinical Oncology(ASCO) meeting in Chicago show that a novel combination regimenbased on Merck KGaA’s oral 5-fluorouracil (5-FU) therapy UFT(tegafur–uracil) plus leucovorin (LV) has shown an excellentresponse rate in the first-line treatment of metastatic colorectalca...

Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

- Cipralex Better Tolerated and at Least as Effective inLong-Term Treatment H. Lundbeck A/S announces new study data published today in thejournal Current Medical Research and Opinion, demonstrating thatCipralex(R) (escitalopram) was superior to duloxetine in the acutetreatment of patients with major depressive disorder (MDD)...

Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and PAION AG today announced topline results ofthe DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with thecompound Desmoteplase. The Phase III study was designed toinvestigate the improvement of clinical outcome in patients withacute ischemic stroke treated with Desmoteplase within 3 to 9 hoursafter onset of...

Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo

PAION AG and US Partner Forest Laboratories, Inc. TodayAnnounced the Top Line Results of the DIAS-2 (Desmoteplase In AcuteIschemic Stroke) Study with the Compound Desmoteplase Aachen (Germany), May 31st, 2007 - PAION AG (Frankfurt StockExchange, Prime Standard: PA8) and its US partner ForestLaboratories, Inc. (NYSE: FRX) today announced topline results ofthe DIAS-2 (Desmoteplase In...

Introgen's Advexin Demonstrates Clinical Benefit in Inherited Cancer

AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--IntrogenTherapeutics, Inc. (NASDAQ:INGN) announced today the publication ofdata describing the dramatic clinical benefit of its lead productAdvexin in a patient with a rare inherited form of cancer known asLi-Fraumeni Syndrome (LFS), a genetic disorder characterized byinherited mutations i...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced that DAYTRANA(TM) (methylphenidate transdermal system),the first and only non-oral medication approved for treatment ofAttention Deficit Hyperactivity Disorder (ADHD) in children aged 6to 12 years, provided significant improvement in symptom controland tolerability, according to results of a 12-month open-labelstudy pre...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drugdocetaxel currently offers the best treatment forandrogen-independent prostate cancer. That is the result of a nowpublished clinical trial that compared the efficacy of the two mostwidely used chemotherapy drugs. When using docetaxel, the risk ofdisease progression was cut by more than 50% than when using thenext-best chemotherapy drug.<...

Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug Candidate, Sphingomab

Sphingomab Shows Near-Complete Mitigation of ChoroidalNeovascularization (CNV) in an AMD Model SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- Lpath, Inc. ,the category leader in therapeutic agents against bioactive lipids,reported compelling proof-of-concept data in a standard animalmodel of human age-related macular degeneration (AMD). The results were presented at the annual me...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

WASHINGTON, May 21, 2007 /PRNewswire/ -- A new studydemonstrated that the active ingredient in Amitiza (lubiprostone),given 8 mcg twice a day, may improve symptom relief rates in adultswith irritable bowel syndrome with constipation (IBS-C). Theseresults were presented as a late-breaker at Digestive Disease Week2007, the largest annual international meeting of digestive diseasespecialist...

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy

Data Also Show Nebivolol Lowers Blood Pressure in Obese andNon-Obese Hypertensive Patients CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. today presented positive data from two clinicalstudies and one pooled analysis of nebivolol, a selective beta1-blocker with vasodilating properties currently under review bythe U.S. Food and Drug Administration (FDA) for the tr...

Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

WASHINGTON, May 21, 2007/PRNewswire-FirstCall/ -- Bristol-MyersSquibb Company (NYSE: BMY) today announced new data from studyETV-079, which showed that treatment with Baraclude (entecavir)demonstrated greater viral load reduction than adefovir at 48 weeks-- a result that was also seen at weeks 12 (primary endpoint) and24. These data from an open-label, randomized viral kinetics studyof 6...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Toleratedin NIH-Sponsored Phase 1/2 Study NEEDHAM, MA (May 18, 2007) - AVANT Immunotherapeutics, Inc.(Nasdaq: AVAN) announced today positive preliminary results from aninvestigational double-blind, placebo-controlled Phase 1/2dose-escalating clinical trial of its typhoid fever vaccinecandidate, Ty800, in healthy volunteers. The...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2007 - AVANTImmunotherapeutics, Inc. (Nasdaq: AVAN) announced today positivepreliminary results from an investigational double-blind,placebo-controlled Phase 1/2 dose-escalating clinical trial of itstyphoid fever vaccine candidate, Ty800, in healthy volunteers. Theresearchers found the single-dose, oral vaccine to be welltolerated and immunogenic, wi...

Gardasil Demonstrates Up to 100% Efficacy

- In the Prevention of Cervical Cancer and Other HumanPapillomavirus Related Diseases After an Additional Year of FollowUp in Large Phase III Clinical Studies Which Included More Than17,000 Women New England Journal of Medicine publishes the most comprehensiveand robust clinical data for any Human Papillomavirus vaccine LYON, France, 10th May2007 – New clinical st...

Discovery's KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties

Discovery's KL-4 Surfactant Technology Demonstrates NovelAnti-Inflammatory Properties New Surfaxin Data Presented At the 2007 Pediatric AcademicSocieties Annual Meeting WARRINGTON, Pa., May 9, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announced that new data supportingthe anti-inflammatory properties of its novel KL-4 surfactant(lucinactant) replacement tec...